Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastasic Breast Cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Trastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastasic Breast Cancer
Authors
Keywords
-
Journal
Nanomaterials
Volume 9, Issue 12, Pages 1793
Publisher
MDPI AG
Online
2019-12-17
DOI
10.3390/nano9121793
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study
- (2019) Alberto Ocana et al. BREAST CANCER RESEARCH AND TREATMENT
- Assessment of doxorubicin delivery devices based on tailored bare polycaprolactone against glioblastoma
- (2019) Enrique Niza et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells
- (2019) Elena Díaz-Rodríguez et al. CANCER LETTERS
- Ligand‐Installed Nanocarriers toward Precision Therapy
- (2019) Peng Mi et al. ADVANCED MATERIALS
- Poly(Cyclohexene Phthalate) Nanoparticles for Controlled Dasatinib Delivery in Breast Cancer Therapy
- (2019) Niza et al. Nanomaterials
- Magnetically Guided Self-Assembled Protein Micelles for Enhanced Delivery of Dasatinib to Human Triple-Negative Breast Cancer Cells
- (2018) Sally A. Sabra et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study
- (2017) Alberto Ocana et al. Oncotarget
- Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP)
- (2017) Xiao-Long Qian et al. PLoS One
- Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
- (2016) Nazila Kamaly et al. CHEMICAL REVIEWS
- Micellar delivery of dasatinib for the inhibition of pathologic cellular processes of the retinal pigment epithelium
- (2016) Qingqing Li et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance
- (2016) Shizhu Chen et al. Nanomedicine-Nanotechnology Biology and Medicine
- Dasatinib-loaded albumin nanoparticles possess diminished endothelial cell barrier disruption and retain potent anti-leukemia cell activity
- (2016) Chunling Dong et al. Oncotarget
- Monoclonal antibody-tagged polyethylenimine (PEI)/poly(lactide) (PLA) nanoparticles for the enhanced delivery of doxorubicin in HER-positive breast cancers
- (2016) Ning Cui et al. RSC Advances
- Catalytic behaviour in the ring-opening polymerisation of organoaluminiums supported by bulky heteroscorpionate ligands
- (2015) Jose A. Castro-Osma et al. DALTON TRANSACTIONS
- The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents
- (2013) C. Dos Santos et al. BLOOD
- Personalized nanomedicine: future medicine for cancer treatment
- (2013) Farooq A. Shiekh International Journal of Nanomedicine
- Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization
- (2013) Huile Gao et al. Scientific Reports
- Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors
- (2011) J. C. Montero et al. CLINICAL CANCER RESEARCH
- A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery
- (2010) Yutao Liu et al. BIOMATERIALS
- Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors
- (2010) John Araujo et al. CANCER TREATMENT REVIEWS
- Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy
- (2010) Shin et al. International Journal of Nanomedicine
- Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
- (2009) G E Konecny et al. BRITISH JOURNAL OF CANCER
- Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin
- (2009) P. Ceppi et al. MOLECULAR CANCER THERAPEUTICS
- Discrete Heteroscorpionate Lithium and Zinc Alkyl Complexes. Synthesis, Structural Studies, and ROP of Cyclic Esters
- (2008) Carlos Alonso-Moreno et al. ORGANOMETALLICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More